中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2010年
8期
1144-1146,后插二
,共4页
贺兴军%贾瑞鹏%王自正%许露伟%邵国强%黄培林%曹朴
賀興軍%賈瑞鵬%王自正%許露偉%邵國彊%黃培林%曹樸
하흥군%가서붕%왕자정%허로위%소국강%황배림%조박
32P-磷酸铬%前列腺癌%淋巴结转移%近距离放射治疗
32P-燐痠鉻%前列腺癌%淋巴結轉移%近距離放射治療
32P-린산락%전렬선암%림파결전이%근거리방사치료
32P-chromic phosphate%Prostatic carcinoma%Lymphatic metastasis%Implantation brachytherapy
目的 观察32P-磷酸铬-聚L-乳酸(32P-CP-PLLA)缓释粒子植入对裸鼠前列腺癌实体瘤和区域淋巴结转移灶的治疗作用.方法 建立裸鼠原位前列腺癌及淋巴结转移模型,4周后分别进行高、中、低剂量(剂量分别为3.7、7.4、14.8 MBq)32P-CP-PLLA缓释粒子瘤体局部植入,观察(1)不同剂量32P-CP-PLLA缓释粒子的体内生物学分布;(2)上述缓释粒子对瘤体和淋巴结病理形态学影响以及抑瘤率;(3)观察血WBC和PLT变化,研究其血液不良反应.结果 SPECT显示32P-CP-PLLA缓释粒子植入后主要聚集在瘤体局部和区域淋巴结,形态学检查显示实体瘤和区域淋巴结转移灶瘤组织呈出血、坏死性改变;抑瘤率与给药剂量正相关,给药剂量为3.7、7.4、14.8 MBq,抑瘤率分别为:(70.16±5.48)%、(80.18±5.84)%、(84.97±4.79)%,无明显骨髓抑制反应.结论 32P-CP-PLLA缓释粒子瘤体局部植入对前列腺癌肿瘤组织和区域性淋巴结转移灶具有杀伤作用.
目的 觀察32P-燐痠鉻-聚L-乳痠(32P-CP-PLLA)緩釋粒子植入對裸鼠前列腺癌實體瘤和區域淋巴結轉移竈的治療作用.方法 建立裸鼠原位前列腺癌及淋巴結轉移模型,4週後分彆進行高、中、低劑量(劑量分彆為3.7、7.4、14.8 MBq)32P-CP-PLLA緩釋粒子瘤體跼部植入,觀察(1)不同劑量32P-CP-PLLA緩釋粒子的體內生物學分佈;(2)上述緩釋粒子對瘤體和淋巴結病理形態學影響以及抑瘤率;(3)觀察血WBC和PLT變化,研究其血液不良反應.結果 SPECT顯示32P-CP-PLLA緩釋粒子植入後主要聚集在瘤體跼部和區域淋巴結,形態學檢查顯示實體瘤和區域淋巴結轉移竈瘤組織呈齣血、壞死性改變;抑瘤率與給藥劑量正相關,給藥劑量為3.7、7.4、14.8 MBq,抑瘤率分彆為:(70.16±5.48)%、(80.18±5.84)%、(84.97±4.79)%,無明顯骨髓抑製反應.結論 32P-CP-PLLA緩釋粒子瘤體跼部植入對前列腺癌腫瘤組織和區域性淋巴結轉移竈具有殺傷作用.
목적 관찰32P-린산락-취L-유산(32P-CP-PLLA)완석입자식입대라서전렬선암실체류화구역림파결전이조적치료작용.방법 건립라서원위전렬선암급림파결전이모형,4주후분별진행고、중、저제량(제량분별위3.7、7.4、14.8 MBq)32P-CP-PLLA완석입자류체국부식입,관찰(1)불동제량32P-CP-PLLA완석입자적체내생물학분포;(2)상술완석입자대류체화림파결병리형태학영향이급억류솔;(3)관찰혈WBC화PLT변화,연구기혈액불량반응.결과 SPECT현시32P-CP-PLLA완석입자식입후주요취집재류체국부화구역림파결,형태학검사현시실체류화구역림파결전이조류조직정출혈、배사성개변;억류솔여급약제량정상관,급약제량위3.7、7.4、14.8 MBq,억류솔분별위:(70.16±5.48)%、(80.18±5.84)%、(84.97±4.79)%,무명현골수억제반응.결론 32P-CP-PLLA완석입자류체국부식입대전렬선암종류조직화구역성림파결전이조구유살상작용.
Objective To study the anticancer effects of 32P-chromic phosphate-poly ( L-lactide) (32P-CP-PLI^A) in nude mice with lymphatic metastasis of prostatic carcinoma after implantation brachytherapy. Methods The nude mice were intratumorally implanted with 32P-CP-PLLA of 3.7, 7.4, 14.8 MBq after prostatic carcinoma solid tumor model was established for four weeks. The distribution of 32P in body was observed. The morphology of the tumor and regional lymph nodes was examined. White blood cells and platelets were counted in peripheral blood. Results 32P mainly remained in the tumor and regional lymph nodes. Morphological examination demonstrated that the solid tumor foci necrosed thoroughly, normal structure of regional lymph nodes disappeared, which was replaced by necrotic tissue and hemorrhage. The tumor growth inhibition rate was positively correlated to administration doses. When the doses were 3.7, 7.4, 14.8 MBq, the tumor growth inhibition rate was (70.16 ±5.48)% , (80.18 ±5.84)% , (84.97 ±4.79)% , respectively. No obvious bone marrow depressions were detected. Conclusion The intratumoral implantation with 32P-CP-PLLA can produce anticancer effects on the solid tumor foci and regional lymph nodes.